Stroke risk in atrial fibrillation
Total Score
Low risk. No anticoagulation needed.
Disclaimer: The clinical scoring and algorithms on this platform are intended strictly for professional informational purposes. They do not constitute a definitive medical diagnosis, treatment, or clinical decision. The final judgment and responsibility lie with the treating physician.
Yasal Uyarı: Bu platformdaki klinik skorlamalar ve algoritmalar yalnızca sağlık profesyonellerini bilgilendirme amaçlıdır. Herhangi bir kesin tıbbi teşhis, tedavi veya klinik karar yerine geçemez. Nihai karar ve sorumluluk hastayı yatak başında değerlendiren hekime aittir.
The CHA2DS2-VASc score is a globally endorsed clinical risk stratification tool used to estimate the annual risk of thromboembolism (stroke, TIA, or systemic embolism) in patients with non-valvular atrial fibrillation. It guides the decision to initiate oral anticoagulation (OAC) therapy according to AHA/ACC and ESC guidelines.
Female sex is a risk modifier rather than an independent risk factor. In current ESC guidelines, a score of 1 in a female (meaning sex is the only risk factor) does not mandate anticoagulation. Treatment is generally considered at a score of ≥1 for men and ≥2 for women, and strongly recommended at ≥2 for men and ≥3 for women.
Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-272.
Disclaimer: The clinical scoring and algorithms on this platform are intended strictly for professional informational purposes. They do not constitute a definitive medical diagnosis, treatment, or clinical decision. The final judgment and responsibility lie with the treating physician.